B05/CD3

N/A

Report date: 2026/03/19 16:59:36

Base Information

Drug NameB05/CD3
Drug Alias NameMHC antagonist (Affimed)T-cell TandAbs (Affimed)anti-CD3/anti-MHC-MMP1-003 tetravalent bispecific T-cell engager (Affimed/Immatics)HLA-A02-binding peptide MMP1-003 targeting bispecific antibodies (Affimed/Immatics)CD3-targeting antibodies (Affimed) +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionHLA Class I Histocompatibility Antigen, A-2 alpha Chain modulatorsT cell surface glycoprotein CD3 modulatorsMatrix metalloproteinase-1 modulators
TargetsHLA Class I Histocompatibility Antigen, A-2 alpha ChainT cell surface glycoprotein CD3Matrix metalloproteinase-1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAffimed Nv
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAffimed NvImmatics NV
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A